Evidence map›Paper›PMID 32125540›Full record

ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2020

Eye tracking metrics to screen and assess cognitive impairment in patients with neurological disorders.

Ling Tao, Quan Wang, Ding Liu, Jing Wang, Ziqing Zhu, Li Feng

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 2 pooled it
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. A novel eye-tracking digital marker outperforms plasma biomarkers in detecting cognitive impairment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ling TaoXiangYa School of Medicine, Central South University, Changsha, Hunan, China.
Quan WangKey Laboratory of Biomedical Spectroscopy of Xi' An, Key Laboratory of Spectral Imaging technology, Xi'an, Institute of Optics and Precision Mechanics (XIOPM), Chinese Academy of Sciences, Xi' An, China.
Ding LiuDepartment of Neurology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jing WangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Ziqing ZhuXiangYa School of Medicine, Central South University, Changsha, Hunan, China.
Li FengDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China. fenglihx@163.com.ORCID http://orcid.org/0000-0001-7658-1399
Central South University · CNChinese Academy of Sciences · CN

Funding

National Natural Science Foundation of China grant nos. 81771407
6 · The paper itself

Abstract

purpose of reviewEye tracking is a powerful method to investigate the relationship between behavior and neural mechanisms. In recent years, eye movement analysis has been used in patients with neurological disorders to assess cognitive function. In this review, we explore the latest eye tracking researches in neurological disorders that are commonly associated with cognitive deficits, specifically, amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and epilepsy. We focus on the application of ocular measures in these disorders, with the goal of understanding how eye tracking technology can be used in the clinical setting.

findingsEye tracking tasks (especially saccadic tasks) are often used as an adjunct to traditional scales for cognitive assessment. Eye tracking data confirmed that executive dysfunction is common in PD and ALS, whereas AD and MS are characterized by attention deficits. Research in evaluating cognitive function in epilepsy using eye tracking is still in its early stages, but this approach has shown advantages as a sensitive quantitative method with high temporal and spatial resolution. Eye tracking technology can facilitate the assessment of cognitive impairment with higher temporal resolution and finer granularity than traditional cognitive assessment. Oculomotor data collected during cognitive tasks can provide insight into biological processes. Eye tracking provides a nonverbal and less cognitively demanding method of measuring disease progression in cognitively impaired patients.

Indexed as

Amyotrophic Lateral SclerosisCognition DisordersCognitive DysfunctionEye-Tracking TechnologyHumansNeuropsychological TestsAlzheimer’s diseaseAmyotrophic lateral sclerosisCognitionEpilepsyEye trackingMultiple sclerosisNeurologyParkinson’s disease

Identifiers

PMID32125540
OpenAlexW3010145018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.